Structural Domains and Molecular Lifestyles of Insulin and Its Precursors in the Pancreatic Beta Cell*
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chapter 7: Monogenic Forms of Diabetes
CHAPTER 7 MONOGENIC FORMS OF DIABETES Mark A. Sperling, MD, and Abhimanyu Garg, MD Dr. Mark A. Sperling is Emeritus Professor and Chair, University of Pittsburgh, Department of Pediatrics, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA. Dr. Abhimanyu Garg is Professor of Internal Medicine and Chief of the Division of Nutrition and Metabolic Diseases at University of Texas Southwestern Medical Center, Dallas, TX. SUMMARY Types 1 and 2 diabetes have multiple and complex genetic influences that interact with environmental triggers, such as viral infections or nutritional excesses, to result in their respective phenotypes: young, lean, and insulin-dependence for type 1 diabetes patients or older, overweight, and often manageable by lifestyle interventions and oral medications for type 2 diabetes patients. A small subset of patients, comprising ~2%–3% of all those diagnosed with diabetes, may have characteristics of either type 1 or type 2 diabetes but have single gene defects that interfere with insulin production, secretion, or action, resulting in clinical diabetes. These types of diabetes are known as MODY, originally defined as maturity-onset diabetes of youth, and severe early-onset forms, such as neonatal diabetes mellitus (NDM). Defects in genes involved in adipocyte development, differentiation, and death pathways cause lipodystrophy syndromes, which are also associated with insulin resistance and diabetes. Although these syndromes are considered rare, more awareness of these disorders and increased availability of genetic testing in clinical and research laboratories, as well as growing use of next generation, whole genome, or exome sequencing for clinically challenging phenotypes, are resulting in increased recognition. A correct diagnosis of MODY, NDM, or lipodystrophy syndromes has profound implications for treatment, genetic counseling, and prognosis. -
Report of the Expert Committee on the Diagnosis and Classification Of
COMMITTEE REPORT Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS* he current classification and diagno- nosis of diabetes were warranted. The in insulin secretion, insulin action, or sis of diabetes used in the U.S. was Committee met on multiple occasions both. The chronic hyperglycemia of dia- T developed by the National Diabetes and widely circulated a draft report of betes is associated with long-term dam- Data Group (NDDG) and published in their findings and preliminary recom- age, dysfunction, and failure of various 1979 (1). The impetus for the classifica- mendations to the international diabe- organs, especially the eyes, kidneys, tion and diagnosis scheme proposed then tes community. Based on the numerous nerves, heart, and blood vessels. holds true today. That is, comments and suggestions received, in- Several pathogenic processes are in- cluding the opportunity to review unpub- volved in the development of diabetes. the growth of knowledge regarding the eti- lished data in detail, the Committee These range from autoimmune destruc- ology and pathogenesis of diabetes has led discussed and revised numerous drafts of tion of the -cells of the pancreas with many individuals and groups in the diabe- a manuscript that culminated in this pub- consequent insulin deficiency to abnor- tes community to express the need for a lished document. malities that result in resistance to insulin revision of the nomenclature, diagnostic This report is divided into four sec- action. The basis of the abnormalities in criteria, and classification of diabetes. -
(GLP-1) in Transgenic Plants
The Open Biotechnology Journal, 2009, 3, 57-66 57 Open Access A Proficient Approach to the Production of Therapeutic Glucagon-Like Peptide-1 (GLP-1) in Transgenic Plants M. Brandsma1, X. Wang1, H. Diao2,3, S.E. Kohalmi1, A.M. Jevnikar2,3 and S. Ma1,2,3,* 1Department of Biology, University of Western Ontario, London, Ontario, N6A 5B7, Canada 2Transplantation Immunology Group, Lawson Health Research Institute, London, Ontario, N6A 4G5, Canada 3Plantigen Inc., 700 Collip Circle, London, Ontario, N6G 4X8, Canada Abstract: Glucagon-like peptide-1 (GLP-1) is a small peptide hormone with potent insulinotropic activity and represents a promising new therapeutic tool for the treatment of diabetes. Like many other therapeutic peptides, GLP-1 is commonly produced using chemical synthesis methods, but is limited by product quantity and cost. The advent of recombinant DNA technology offers the possibility of producing GLP-1 inexpensively and in vast quantities. In this study, transgenic plants were used as a recombinant expression platform for the production of GLP-1 as a large multimeric protein. A synthetic gene encoding ten sequential tandem repeats of GLP-1 sequence (GLP-1x10) was produced and introduced into tobacco plants. Transcriptional expression of the GLP1x10 gene in transgenic plants was confirmed by RT-PCR. Western blot analysis showed that the GLP-1x10 protein efficiently accumulated in transgenic plants, with an accumulation level as high as 0.15% of total soluble protein in leaves. Importantly, insulin secretion assays using a mouse pancreatic cell line (MIN6), showed that plant-derived GLP-1 in its synthetic decamer form, retained its ability to stimulate cellular insulin secretion, although with reduced efficacy. -
Divergent Genes in Gerbils: Prevalence, Relation to GC-Biased Substitution, and Phenotypic Relevance Yichen Dai, Rodrigo Pracana and Peter W
Dai et al. BMC Evolutionary Biology (2020) 20:134 https://doi.org/10.1186/s12862-020-01696-3 RESEARCH ARTICLE Open Access Divergent genes in gerbils: prevalence, relation to GC-biased substitution, and phenotypic relevance Yichen Dai, Rodrigo Pracana and Peter W. H. Holland* Abstract Background: Two gerbil species, sand rat (Psammomys obesus) and Mongolian jird (Meriones unguiculatus), can become obese and show signs of metabolic dysregulation when maintained on standard laboratory diets. The genetic basis of this phenotype is unknown. Recently, genome sequencing has uncovered very unusual regions of high guanine and cytosine (GC) content scattered across the sand rat genome, most likely generated by extreme and localized biased gene conversion. A key pancreatic transcription factor PDX1 is encoded by a gene in the most extreme GC-rich region, is remarkably divergent and exhibits altered biochemical properties. Here, we ask if gerbils have proteins in addition to PDX1 that are aberrantly divergent in amino acid sequence, whether they have also become divergent due to GC-biased nucleotide changes, and whether these proteins could plausibly be connected to metabolic dysfunction exhibited by gerbils. Results: We analyzed ~ 10,000 proteins with 1-to-1 orthologues in human and rodents and identified 50 proteins that accumulated unusually high levels of amino acid change in the sand rat and 41 in Mongolian jird. We show that more than half of the aberrantly divergent proteins are associated with GC biased nucleotide change and many are in previously defined high GC regions. We highlight four aberrantly divergent gerbil proteins, PDX1, INSR, MEDAG and SPP1, that may plausibly be associated with dietary metabolism. -
Genes in Eyecare Geneseyedoc 3 W.M
Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease. -
Intraceuular Transport and Sorting of Mutant Human Proinsulins That Fail to Form Hexamers David Quinn,* Lelio Orci,* Mariella Ravazzola,~ and Hsiao-Ping H
IntraceUular Transport and Sorting of Mutant Human Proinsulins that Fail to Form Hexamers David Quinn,* Lelio Orci,* Mariella Ravazzola,~ and Hsiao-Ping H. Moore* * Department of Molecular and Cell Biology, Life Sciences Addition, University of California, Berkeley, California 94720; and *Department of Morphology, University of Geneva Medical School, Geneva, Switzerland Abstract. Human proinsulin and insulin oligomerize both dimers and hexamers. The mutants were trans- to form dimers and hemmers. It has been suggested fected into the mouse pituitary AtT-20 cells, and their that the ability of prohormones to self associate and ability to be sorted into regulated secretory granules form aggregates may be responsible for the sorting was compared to wild-type insulin. We found that process at the trans-Golgi. To examine whether insulin while B10His-~p is sorted somewhat less efficiently than oligomerization is required for proper sorting into reg- wild-type insulin as reported previously (Carroll, R. J., ulated storage granules, we have constructed point R. E. Hammer, S. J. Chan, H. H. Swift, A. H. Ruben- mutations in human insulin B chain that have been stein, and D. E Steiner. 1988. Proc. Natl. Acad. Sci. previously shown to prevent formation of insulin hexa- USA. 85:8943-8947; Gross, D. J., P. A. Halban, C. R. mers (Brange, J., U. Ribel, J. E Hansen, G. Dodson, Kahn, G. C. Weir, and L. Villa-Kumaroff. 1989. Proc. M. T. Hansen, S. Havelund, S. G. Melberg, E Norris, Natl. Acad. Sci. USA. 86:4107-4111). B9Se~p is tar- K. Norris, L. Snel, A. R. Sorensen, and H. -
Isolation and Proteomics of the Insulin Secretory Granule
H OH metabolites OH Review Isolation and Proteomics of the Insulin Secretory Granule Nicholas Norris , Belinda Yau * and Melkam Alamerew Kebede Charles Perkins Centre, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia; [email protected] (N.N.); [email protected] (M.A.K.) * Correspondence: [email protected] Abstract: Insulin, a vital hormone for glucose homeostasis is produced by pancreatic beta-cells and when secreted, stimulates the uptake and storage of glucose from the blood. In the pancreas, insulin is stored in vesicles termed insulin secretory granules (ISGs). In Type 2 diabetes (T2D), defects in insulin action results in peripheral insulin resistance and beta-cell compensation, ultimately leading to dysfunctional ISG production and secretion. ISGs are functionally dynamic and many proteins present either on the membrane or in the lumen of the ISG may modulate and affect different stages of ISG trafficking and secretion. Previously, studies have identified few ISG proteins and more recently, proteomics analyses of purified ISGs have uncovered potential novel ISG proteins. This review summarizes the proteins identified in the current ISG proteomes from rat insulinoma INS-1 and INS-1E cell lines. Here, we also discuss techniques of ISG isolation and purification, its challenges and potential future directions. Keywords: insulin secretory granule; beta-cells; granule protein purification 1. Insulin Granule Biogenesis and Function Citation: Norris, N.; Yau, B.; Kebede, The insulin secretory granule (ISG) is the storage vesicle for insulin in pancreatic M.A. Isolation and Proteomics of the beta-cells. It was long treated as an inert carrier for insulin but is now appreciated as a Insulin Secretory Granule. -
Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes
258 Diabetes Care Volume 42, February 2019 Proinsulin Secretion Is a Emily K. Sims,1,2 Henry T. Bahnson,3 Julius Nyalwidhe,4 Leena Haataja,5 Persistent Feature of Type 1 Asa K. Davis,3 Cate Speake,3 Linda A. DiMeglio,1,2 Janice Blum,6 Diabetes Margaret A. Morris,7 Raghavendra G. Mirmira,1,2,8,9,10 7 10,11 Diabetes Care 2019;42:258–264 | https://doi.org/10.2337/dc17-2625 Jerry Nadler, Teresa L. Mastracci, Santica Marcovina,12 Wei-Jun Qian,13 Lian Yi,13 Adam C. Swensen,13 Michele Yip-Schneider,14 C. Max Schmidt,14 Robert V. Considine,9 Peter Arvan,5 Carla J. Greenbaum,3 Carmella Evans-Molina,2,8,9,10,15 and the T1D Exchange Residual C-peptide Study Group* OBJECTIVE Abnormally elevated proinsulin secretion has been reported in type 2 and early type 1 diabetes when significant C-peptide is present. We questioned whether individuals with long-standing type 1 diabetes and low or absent C-peptide secretory capacity retained the ability to make proinsulin. RESEARCH DESIGN AND METHODS C-peptide and proinsulin were measured in fasting and stimulated sera from 319 subjects with long-standing type 1 diabetes (‡3 years) and 12 control subjects without diabetes. We considered three categories of stimulated C-peptide: 1) 1Department of Pediatrics, Indiana University ‡ 2 School of Medicine, Indianapolis, IN C-peptide positive, with high stimulated values 0.2 nmol/L; ) C-peptide posi- 2 tive, with low stimulated values ‡0.017 but <0.2 nmol/L; and 3)C-peptide Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indian- <0.017 nmol/L. -
Ectopic Expression of Glucagon-Like Peptide 1 for Gene Therapy of Type II Diabetes
Gene Therapy (2007) 14, 38–48 & 2007 Nature Publishing Group All rights reserved 0969-7128/07 $30.00 www.nature.com/gt ORIGINAL ARTICLE Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes GB Parsons, DW Souza, H Wu, D Yu, SG Wadsworth, RJ Gregory and D Armentano Department of Molecular Biology, Genzyme Corporation, Framingham, MA, USA Glucagon-like peptide 1 (GLP-1) is a promising candidate for lowered both the fasting and random-fed hyperglycemia the treatment of type II diabetes. However, the short in vivo present in these animals. Because the insulinotropic actions half-life of GLP-1 has made peptide-based treatments of GLP-1 are glucose dependent, no evidence of hypogly- challenging. Gene therapy aimed at achieving continuous cemia was observed. Improved glucose homeostasis was GLP-1 expression presents one way to circumvent the rapid demonstrated by improvements in %HbA1c (glycated he- turnover of GLP-1. We have created a GLP-1 minigene that moglobin) and in glucose tolerance tests. GLP-1-treated can direct the secretion of active GLP-1 (amino acids 7–37). animals had higher circulating insulin levels and increased Plasmid and adenoviral expression vectors encoding the 31- insulin immunostaining of pancreatic sections. GLP-1-treated amino-acid peptide linked to leader sequences required for ZDF rats showed diminished food intake and, in the first few secretion of GLP-1 yielded sustained levels of active GLP-1 weeks following vector administration, a diminished weight that were significantly greater than endogenous levels. gain. These results demonstrate the feasibility of gene Systemic administration of expression vectors to animals therapy for type II diabetes using GLP-1 expression vectors. -
The Un-Design and Design of Insulin: Structural Evolution
THE UN-DESIGN AND DESIGN OF INSULIN: STRUCTURAL EVOLUTION WITH APPLICATION TO THERAPEUTIC DESIGN By NISCHAY K. REGE Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Biochemistry Dissertation Advisor: Dr. Michael A. Weiss CASE WESTERN RESERVE UNIVERSITY August, 2018 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Nischay K. Rege candidate for the degree of Doctor of Philosophy*. Committee Chair Paul Carey Committee Member Michael Weiss Committee Member Faramarz Ismail-Beigi Committee Member George Dubyak Date of Defense: June 26th, 2018 *We also certify that written approval has been obtained for any proprietary material contained therein. Dedication This thesis is dedicated to my mother, Dipti, whose constant love and faith have never failed, to my father, Kiran, who taught me of the virtue of curiosity, and to my wife, Shipra, whose kindness and companionship have given me enough strength for eight lifetimes. i Table of Contents Dedication ..................................................................................................................................... i Table of Contents ......................................................................................................................... ii List of Tables ............................................................................................................................... v List of Figures ........................................................................................................................... -
Signaling Peptides in Plants
lopmen ve ta e l B D io & l l o l g e y C Cell & Developmental Biology Ghorbani, et al., Cell Dev Biol 2014, 3:2 ISSN: 2168-9296 DOI: 10.4172/2168-9296.1000141 Review Article Open Access Signaling Peptides in Plants Sarieh Ghorbani1,2, Ana Fernandez1,2, Pierre Hilson3,4 and Tom Beeckman1,2* 1Department of Plant Systems Biology, VIB, B-9052 Ghent, Belgium 2Department of Plant Biotechnology and Bioinformatics, Ghent University, B-9052 Ghent, Belgium 3INRA, UMR1318, Institut Jean-Pierre Bourgin, RD10, F-78000 Versailles, France 4AgroParisTech, Institut Jean-Pierre Bourgin, RD10, F-78000 Versailles, France *Corresponding author: Tom Beeckman, Department of Plant Systems Biology, VIB, B-9052 Ghent, Belgium, Tel: 32-0-93313830; E-mail: [email protected] Rec date: May 03, 2014; Acc date: Jun 16, 2014; Pub date: Jun 18, 2014 Copyright: © 2014 Ghorbani S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract In multicellular organisms, growth and development need to be precisely coordinated and are strongly relying on positional information. Positional control is achieved through exchanges of molecular messages between cells and tissues by means of cell-to-cell communication mechanisms. Especially in plants, accurate and well-controlled cell-to-cell communication networks are essential because of the complete absence of cell mobility and the presence of rigid cell walls. For many years, phytohormones were thought to be the main messengers exchanged between cells. -
Glucagon-Like Peptide-1 and Its Class BG Protein–Coupled Receptors
1521-0081/68/4/954–1013$25.00 http://dx.doi.org/10.1124/pr.115.011395 PHARMACOLOGICAL REVIEWS Pharmacol Rev 68:954–1013, October 2016 Copyright © 2016 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: RICHARD DEQUAN YE Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng, and Ming-Wei Wang Division of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (C.d.G.); School of Biomedical Sciences, University of Leeds, Leeds, United Kingdom (D.D.); Drug Discovery Biology Theme and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia (D.W., P.M.S., M.M.F.); Protein and Peptide Chemistry, Global Research, Novo Nordisk A/S, Måløv, Denmark (J.La.); Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (L.J.M.); Department of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, Texas (J.-M.A.); Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, Riverside, California (J.Li.); National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (D.Y., C.Z., J.D., M.-W.W.); Heptares Therapeutics, BioPark, Welwyn Garden City, United Kingdom (A.J.H.B.); and School of Pharmacy, Fudan University, Zhangjiang High-Tech Park, Shanghai, China (M.-W.W.) Downloaded from Abstract.